Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million

On Tuesday, Bioventus Inc. BVS reported fourth-quarter adjusted EPS of 15 cents, up from 7 cents, beating the consensus of 8 cents.The medical device company reported sales of $153.6 million, up 13.5% year over year, beating the consensus of$ 145.2 million, driven by double-digit growth in pain treatments and surgical solutions.Pain treatment sales increased 18.7% to $62.8 million, Surgical Solutions sales increased 16.8% to$ 46.43 million and Restorative Therapies sales fell marginally by 0.6% to $25.95 mi ...